Increased inflammatory markers identified in the dorsolateral prefrontal cortex of individuals with schizophrenia

Molecular Psychiatry

Volumn 18, Issue 2, 2013, Pages 206-214

  Fillman, S G ^a,b,c   Cloonan, N ^d   Catts, V S ^a,b,c   Miller, L C ^e   Wong, J ^f   Mccrossin, T ^g   Cairns, M ^a,h   Weickert, C S ^a,b,c  

^a SCHIZOPHRENIA RESEARCH INSTITUTE   (Australia)

^b NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d UNIVERSITY OF QUEENSLAND   (Australia)

^e CHILDREN'S MEDICAL RESEARCH INSTITUTE   (Australia)

^f UNIVERSITY OF WOLLONGONG   (Australia)

^g UNIVERSITY OF SYDNEY   (Australia)

^h UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

immune; inflammatory; microglia; next generation sequencing; schizophrenia

Indexed keywords

CYTOKINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; RAUWOLFIA ALKALOID; SERPINA 3; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CELL STRUCTURE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; FEMALE; GENETIC TRANSCRIPTION; HUMAN; INFLAMMATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MICROGLIA; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHIZOPHRENIA; SEQUENCE ANALYSIS; UPREGULATION;

ADOLESCENT; ADULT; AGED; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; CHROMOSOME MAPPING; CYTOKINES; FEMALE; GENE EXPRESSION REGULATION; HISTOCOMPATIBILITY ANTIGENS CLASS II; HLA-DP ANTIGENS; HUMANS; MALE; MICROGLIA; MIDDLE AGED; PREFRONTAL CORTEX; RNA, MESSENGER; SCHIZOPHRENIA; SERPINS; YOUNG ADULT;

EID: 84873055619     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2012.110     Document Type: Article

References (79)

1. Arion D, Unger T, Lewis DA, Levitt P, Mirnics K. Molecular evidence for increased expression of genes related to immune and chaperone function in the prefrontal cortex in schizophrenia. Biol Psychiatry 2007; 62: 711-721.
2. Aston C, Jiang L, Sokolov BP. Microarray analysis of postmortem temporal cortex from patients with schizophrenia. J Neurosci Res 2004; 77: 858-866.
3. Hakak Y, Walker JR, Li C, Wong WH, Davis KL, Buxbaum JD et al. Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc Natl Acad Sci USA 2001; 98: 4746-4751.
4. Maycox PR, Kelly F, Taylor A, Bates S, Reid J, Logendra R et al. Analysis of gene expression in two large schizophrenia cohorts identifies multiple changes associated with nerve terminal function. Mol Psychiatry 2009; 14: 1083-1094.
5. Saetre P, Emilsson L, Axelsson E, Kreuger J, Lindholm E, Jazin E. Inflammationrelated genes up-regulated in schizophrenia brains. BMC Psychiatry 2007; 7: 46.
6. Mirnics K, Middleton FA, Marquez A, Lewis DA, Levitt P. Molecular characterization of schizophrenia viewed by microarray analysis of gene expression in prefrontal cortex. Neuron 2000; 28: 53-67.
7. Wang Z, Gerstein M, Snyder M. RNA-Seq: A revolutionary tool for transcriptomics. Nat Rev Genet 2009; 10: 57-63.
8. Okoniewski MJ, Miller CJ. Hybridization interactions between probesets in short oligo microarrays lead to spurious correlations. BMC Bioinformatics 2006; 7: 276.
9. Erbag ci AB, Herken H, Ko? ylu? oglu O, Yilmaz N, Tarakçioglu M. Serum IL-1beta, sIL-2R, IL-6, IL-8 and TNF-alpha in schizophrenic patients, relation with symptomatology and responsiveness to risperidone treatment. Mediators Inflamm 2001; 10: 109-115.
10. Ganguli R, Yang Z, Shurin G, Chengappa KN, Brar JS, Gubbi AV et al. Serum interleukin-6 concentration in schizophrenia: Elevation associated with duration of illness. Psychiatry Res 1994; 51: 1-10.
11. Laan W, Grobbee DE, Selten J-P, Heijnen CJ, Kahn RS, Burger H. Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: Results from a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2010; 71: 520-527.
12. Theodoropoulou S, Spanakos G, Baxevanis CN, Economou M, Gritzapis AD, Papamichail MP et al. Cytokine serum levels, autologous mixed lymphocyte reaction and surface marker analysis in never medicated and chronically medicated schizophrenic patients. Schizophr Res 2001; 47: 13-25.
13. Xu M, He L. Convergent evidence shows a positive association of interleukin-1 gene complex locus with susceptibility to schizophrenia in the Caucasian population. Schizophr Res 2010; 120: 131-142.
14. Schwab SG, Hallmayer J, Freimann J, Lerer B, Albus M, Borrmann-Hassenbach M et al. Investigation of linkage and association/linkage disequilibrium of HLA A-, DQA1-, DQB1-, and DRB1-alleles in 69 sib-pair- and 89 trio-families with schizophrenia. Am J Med Genet 2002; 114: 315-320.
15. Ripke S, Sanders AR, Kendler KS, Levinson DF, Sklar P, Holmans PA et al. Genomewide association study identifies five new schizophrenia loci. Nat Genet 2011; 43: 969-976.
16. van Kammen D, McAllister-Sistilli C, Kelley M, Gurklis J, Yao J. Elevated interleukin-6 in schizophrenia. Psychiatry Res 1999; 87: 129-136.
17. Kunz M, Ceresé r KM, Goi PD, Fries GR, Teixeira AL, Fernandes BS et al. Serum levels of IL-6, IL-10 and TNF-a in patients with bipolar disorder and schizophrenia: Differences in pro- and anti-inflammatory balance. Rev Bras Psiquiatr 2011; e-pub ahead of print.
18. Lin A, Kenis G, Bignotti S, Tura GJ, De Jong R, Bosmans E et al. The inflammatory response system in treatment-resistant schizophrenia: Increased serum interleukin-6. Schizophr Res 1998; 32: 9-15.
19. Naudin J, Mege JL, Azorin JM, Dassa D. Elevated circulating levels of IL-6 in schizophrenia. Schizophr Res 1996; 20: 269-273.
20. Zhang XY, Zhou DF, Cao LY, Zhang PY, Wu GY, Shen YC. Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: Relationship to outcome in schizophrenia. J Clin Psychiatry 2004; 65: 940-947.
21. Zhang XY, Zhou DF, Zhang PY, Wu GY, Cao LY, Shen YC. Elevated interleukin-2, interleukin-6 and interleukin-8 serum levels in neuroleptic-free schizophrenia: Association with psychopathology. Schizophr Res 2002; 57: 247-258.
22. Aloisi F. Immune function of microglia. Glia 2001; 36: 165-179.
23. Frank MG, Baratta MV, Sprunger DB, Watkins LR, Maier SF. Microglia serve as a neuroimmune substrate for stress-induced potentiation of CNS pro-inflammatory cytokine responses. Brain Behav Immun 2007; 21: 47-59.
24. Kettenmann H, Hanisch U-K, Noda M, Verkhratsky A. Physiology of microglia. Physiol Rev 2011; 91: 461-553.
25. Doorduin J, de Vries EFJ, Willemsen ATM, de Groot JC, Dierckx RA, Klein HC. Neuroinflammation in schizophrenia-related psychosis: A PET study. J Nucl Med 2009; 50: 1801-1807.
26. van Berckel BN, Bossong MG, Boellaard R, Kloet R, Schuitemaker A, Caspers E et al. Microglia activation in recent-onset schizophrenia: A quantitative (R)-[11C]PK11195 positron emission tomography study. Biol Psychiatry 2008; 64: 820-822.
27. Kurumaji A, Wakai T, Toru M. Decreases in peripheral-type benzodiazepine receptors in postmortem brains of chronic schizophrenics. J Neural Transm 1997; 104: 1361-1370.
28. Weickert CS, Sheedy D, Rothmond DA, Dedova I, Fung S, Garrick T et al. Selection of reference gene expression in a schizophrenia brain cohort. Aust N Z J Psychiatry 2010; 44: 59-70.
29. Wood DLA, Xu Q, Pearson JV, Cloonan N, Grimmond SM. X-MATE: A flexible system for mapping short read data. Bioinformatics 2011; 27: 580-581.
30. Koehler R, Issac H, Cloonan N, Grimmond SM. The uniqueome: A mappability resource for short-tag sequencing. Bioinformatics 2011; 27: 272-274.
31. Weickert CS, Elashoff M, Richards AB, Sinclair D, Bahn S, Paabo S et al. Transcriptome analysis of male-female differences in prefrontal cortical development. Mol Psychiatry 2009; 14: 558-561.
32. Wong J, Webster MJ, Cassano H, Weickert CS. Changes in alternative brain-derived neurotrophic factor transcript expression in the developing human prefrontal cortex. Eur J Neurosci 2009; 29: 1311-1322.
33. Yang Y, Fung SJ, Rothwell A, Tianmei S, Weickert CS. Increased interstitial white matter neuron density in the dorsolateral prefrontal cortex of people with schizophrenia. Biol Psychiatry 2011; 69: 63-70.
34. Bacher J, Wenzig K, Vogler M. SPSS twostep cluster: A first evaluation. Lehrstuhl Soziol 2004.
35. Fung SJ, Webster MJ, Sivagnanasundaram S, Duncan C, Elashoff M, Weickert CS. Expression of interneuron markers in the dorsolateral prefrontal cortex of the developing human and in schizophrenia. Am J Psychiatry 2010; 167: 1479-1488.
36. Wong J, Hyde TM, Cassano HL, Deep-Soboslay A, Kleinman JE, Weickert CS. Promoter specific alterations of brain-derived neurotrophic factor mRNA in schizophrenia. Neuroscience 2010; 169: 1071-1084.
37. Lewis DA, Gonza'lez-Burgos G. Neuroplasticity of neocortical circuits in schizophrenia. Neuropsychopharmacology 2008; 33: 141-165.
38. Bilbo SD, Barrientos RM, Eads AS, Northcutt A, Watkins LR, Rudy JW et al. Early-life infection leads to altered BDNF and IL-1beta mRNA expression in rat hippocampus following learning in adulthood. Brain Behav Immun 2008; 22: 451-455.
39. Bitanihirwe BKY, Peleg-Raibstein D, Mouttet F, Feldon J, Meyer U. Late prenatal immune activation in mice leads to behavioral and neurochemical abnormalities relevant to the negative symptoms of schizophrenia. Neuropsychopharmacology 2010; 35: 2462-2478.
40. Oskvig DB, Elkahloun AG, Johnson KR, Phillips TM, Herkenham M. Maternal immune activation by LPS selectively alters specific gene expression profiles of interneuron migration and oxidative stress in the fetus without triggering a fetal immune response. Brain Behav Immun 2012.
41. Ackerman KD, Martino M, Heyman R, Moyna NM, Rabin BS. Stressor-induced alteration of cytokine production in multiple sclerosis patients and controls. Psychosom Med 1998; 60: 484-491.
42. Maes M, Song C, Lin A, De Jongh R, Van Gastel A, Kenis G et al. The effects of psychological stress on humans: Increased production of pro-inflammatory cytokines and a Th1-like response in stress-induced anxiety. Cytokine 1998; 10: 313-318.
43. You Z, Luo C, Zhang W, Chen Y, He J, Zhao Q et al. Pro- and anti-inflammatory cytokines expression in rat0s brain and spleen exposed to chronic mild stress: Involvement in depression. Behav Brain Res 2011; 225: 135-141.
44. Sirota P, Schild K, Elizur A, Djaldetti M, Fishman P. Increased interleukin-1 and interleukin-3 like activity in schizophrenic patients. Prog Neuro-Psychopharmacol Biol Psychiatry 1995; 19: 75-83.
45. Kim Y-K, Myint A-M, Verkerk R, Scharpe S, Steinbusch H, Leonard B. Cytokine changes and tryptophan metabolites in medication-nai?ve and medication-free schizophrenic patients. Neuropsychobiology 2009; 59: 123-129.
46. Kim YK, Kim L, Lee MS. Relationships between interleukins, neurotransmitters and psychopathology in drug-free male schizophrenics. Schizophr Res 2000; 44: 165-175.
47. Behrens MM, Ali SS, Dao DN, Lucero J, Shekhtman G, Quick KL et al. Ketamineinduced loss of phenotype of fast-spiking interneurons is mediated by NADPHoxidase. Science 2007; 318: 1645-1647.
48. Behrens MM, Ali SS, Dugan LL. Interleukin-6 mediates the increase in NADPHoxidase in the ketamine model of schizophrenia. J Neurosci 2008; 28: 13957-13966.
49. Dugan LL, Ali SS, Shekhtman G, Roberts AJ, Lucero J, Quick KL et al. IL-6 mediated degeneration of forebrain GABAergic interneurons and cognitive impairment in aged mice through activation of neuronal NADPH oxidase. PloS ONE 2009; 4: E5518.
50. Williamson LL, Sholar PW, Mistry RS, Smith SH, Bilbo SD. Microglia and memory: Modulation by early-life infection. J Neurosci 2011; 31: 15511-15521.
51. Tambuyzer BR, Ponsaerts P, Nouwen EJ. Microglia: Gatekeepers of central nervous system immunology. J Leukoc Biol 2009; 85: 352-370.
52. Gonzalez PV, Schio? th HB, Lasaga M, Scimonelli TN. Memory impairment induced by IL-1beta is reversed by alpha-MSH through central melanocortin-4 receptors. Brain Behav Immun 2009; 23: 817-822.
53. Hein AM, Stasko MR, Matousek SB, Scott-McKean JJ, Maier SF, Olschowka JA et al. Sustained hippocampal IL-1beta overexpression impairs contextual and spatial memory in transgenic mice. Brain Behav Immun 2010; 24: 243-253.
54. Oitzl MS, van Oers H, Scho? bitz B, de Kloet ER. Interleukin-1 beta, but not interleukin-6, impairs spatial navigation learning. Brain Res 1993; 613: 160-163.
55. Bayer TA, Buslei R, Havas L, Falkai P. Evidence for activation of microglia in patients with psychiatric illnesses. Neurosci Lett 1999; 271: 126-128.
56. Radewicz K, Garey LJ, Gentleman SM, Reynolds R. Increase in HLA-DR immunoreactive microglia in frontal and temporal cortex of chronic schizophrenics. J Neuropathol Exp Neurol 2000; 59: 137-150.
57. Steiner J, Bielau H, Brisch R, Danos P, Ullrich O, Mawrin C et al. Immunological aspects in the neurobiology of suicide: Elevated microglial density in schizophrenia and depression is associated with suicide. J Psychiatr Res 2008; 42: 151-157.
58. Togo T, Akiyama H, Kondo H, Ikeda K, Kato M, Iseki E et al. Expression of CD40 in the brain of Alzheimer0s disease and other neurological diseases. Brain Res 2000; 885: 117-121.
59. Wierzba-Bobrowicz T, Lewandowska E, Lechowicz W, Stepien? T, Pasennik E. Quantitative analysis of activated microglia, ramified and damage of processes in the frontal and temporal lobes of chronic schizophrenics. Folia Neuropathol 2005; 43: 81-89.
60. Steiner J, Mawrin C, Ziegeler A, Bielau H, Ullrich O, Bernstein H-G et al. Distribution of HLA-DR-positive microglia in schizophrenia reflects impaired cerebral lateralization. Acta Neuropathol 2006; 112: 305-316.
61. Aloisi F, Care A, Borsellino G, Gallo P, Rosa S, Bassani A et al. Production of hemolymphopoietic cytokines (IL-6, IL-8, colony-stimulating factors) by normal human astrocytes in response to IL-1 beta and tumor necrosis factor-alpha. J Immunol 1992; 149: 2358-2366.
62. Lee SC, Liu W, Dickson DW, Brosnan CF, Berman JW. Cytokine production by human fetal microglia and astrocytes. Differential induction by lipopolysaccharide and IL-1 beta. J Immunol 1993; 150: 2659-2667.
63. Ringheim GE, Burgher KL, Heroux JA. Interleukin-6 mRNA expression by cortical neurons in culture: Evidence for neuronal sources of interleukin-6 production in the brain. J Neuroimmunol 1995; 63: 113-123.
64. Wei H, Zou H, Sheikh AM, Malik M, Dobkin C, Brown WT et al. IL-6 is increased in the cerebellum of autistic brain and alters neural cell adhesion, migration and synaptic formation. J Neuroinflammation 2011; 8: 52.
65. Burton MD, Sparkman NL, Johnson RW. Inhibition of interleukin-6 trans-signaling in the brain facilitates recovery from lipopolysaccharide- induced sickness behavior. J Neuroinflammation 2011; 8: 54.
66. Vollenweider F, Herrmann M, Otten U, Nitsch C. Interleukin-6 receptor expression and localization after transient global ischemia in gerbil hippocampus. Neurosci Lett 2003; 341: 49-52.
67. Gadient RA, Otten U. Interleukin-6 and interleukin-6 receptor mRNA expression in rat central nervous system. Ann NY Acad Sci 1995; 762: 403-406.
68. Islam O, Gong X, Rose-John S, Heese K. Interleukin-6 and neural stem cells: More than gliogenesis. Mol Biol Cell 2009; 20: 188-199.
69. Scho? bitz B, de Kloet ER, Sutanto W, Holsboer F. Cellular localization of interleukin 6 mRNA and interleukin 6 receptor mRNA in rat brain. Eur J Neurosci 1993; 5: 1426-1435.
70. Mondelli V, Cattaneo A, Belvederi Murri M, Di Forti M, Handley R, Hepgul N et al. Stress and inflammation reduce brain-derived neurotrophic factor expression in first-episode psychosis: A pathway to smaller hippocampal volume. J Clin Psychiatry 2011; 72: 1677-1684.
71. Sánchez-Mun? oz I, Sánchez-Franco F, Vallejo M, Fernández A, Palacios N, Fernández M et al. Regulation of somatostatin gene expression by brain derived neurotrophic factor in fetal rat cerebrocortical cells. Brain Res 2011; 1375: 28-40.
72. Ehrlich LC, Hu S, Sheng WS, Sutton RL, Rockswold GL, Peterson PK et al. Cytokine regulation of human microglial cell IL-8 production. J Immunol 1998; 160: 1944-1948.
73. Huber AR, Kunkel SL, Todd RF, Weiss SJ. Regulation of transendothelial neutrophil migration by endogenous interleukin-8. Science 1991; 254: 99-102.
74. Mu? ller N, Krause D, Dehning S, Musil R, Schennach-Wolff R, Obermeier M et al. Celecoxib treatment in an early stage of schizophrenia: Results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. Schizophr Res 2010; 121: 118-124.
75. Levin Y, Wang L, Schwarz E, Koethe D, Leweke FM, Bahn S. Global proteomic profiling reveals altered proteomic signature in schizophrenia serum. Mol Psychiatry 2010; 15: 1088-1100.
76. Brown AS. The environment and susceptibility to schizophrenia. Prog Neurobiol 2011; 93: 23-58.
77. Zakharyan R, Petrek M, Arakelyan A, Mrazek F, Atshemyan S, Boyajyan A. Interleukin-6 promoter polymorphism and plasma levels in patients with schizophrenia. Tissue Antigens 2012; e-pub ahead of print.
78. Akhondzadeh S, Tabatabaee M, Amini H, Ahmadi Abhari SA, Abbasi SH, Behnam B. Celecoxib as adjunctive therapy in schizophrenia: A double-blind, randomized and placebo-controlled trial. Schizophr Res 2007; 90: 179-185.
79. Mu? ller N, Schwarz MJ. Immune System and Schizophrenia. Curr Immunol Rev 2010; 6: 213-220.